ArticleBreast cancer research : BCR2020
A deep learning image-based intrinsic molecular subtype classifier of breast tumors reveals tumor heterogeneity that may affect survival.
Article in Breast cancer research : BCR, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 116 citations in OpenAlex.
- Performance of MRI-based deep learning models in differentiation of triple negative breast cancer from other breast cancer subtypes: A systematic review and meta-analysis.European journal of radiology open · 2026Article
- Artificial intelligence and oral microbiome: Reshaping the diagnostic and therapeutic paradigm of OSCC.Clinical and translational medicine · 2026Review
- Noninvasive molecular subtyping of breast cancer using multimodal ultrasound spatiotemporal transformer.NPJ digital medicine · 2026Article
- FT-MDNNMDs: early detection of breast cancer using fine-tuned multi-deep neural networks with TCGA and clinical image datasets.Scientific reports · 2026Article
- Prediction of molecular subtypes from histology: AI-driven analysis of prostate cancer morphological patterns and therapeutic implications.NPJ precision oncology · 2026Article
- Towards interpretable prediction of recurrence risk in breast cancer using pathology foundation models.NPJ digital medicine · 2026Article
- Artificial intelligence for breast cancer management.Communications medicine · 2026Review
- A study on the prognostic assessment of triple-negative breast cancer using habitat analysis of preoperative DCE-MRI subtraction maps.Frontiers in oncology · 2026Article
- A deep learning model based on multiphase DCE-MRI for preoperative prediction of Ki-67 expression in breast cancer.Frontiers in oncology · 2026Article
- Digital pathology and artificial intelligence in breast and gynecologic oncology: from molecular prediction to multimodal integration.Frontiers in oncology · 2026Review
- Predicting MammaPrint Recurrence Risk from Breast Cancer Pathological Images Using a Weakly Supervised Transformer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Advances in machine learning-enhanced microfluidic cell sorting.Science advances · 2025Review
- Article
- WMRCA + : a weighted majority rule-based clustering method for cancer subtype prediction using metabolic gene sets.Hereditas · 2025Article
- Integrating Artificial Intelligence in Next-Generation Sequencing: Advances, Challenges, and Future Directions.Current issues in molecular biology · 2025Review
- SGA-Driven feature selection and random forest classification for enhanced breast cancer diagnosis: A comparative study.Scientific reports · 2025Article
- Enhancing HER2 testing in breast cancer: predicting fluorescence in situ hybridization (FISH) scores from immunohistochemistry images via deep learning.The journal of pathology. Clinical research · 2025Article
- Deep learning-based multi-task prediction of response to neoadjuvant chemotherapy using multiscale whole slide images in breast cancer: A multicenter study.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2025Article
- SHP2 promotes the epithelial-mesenchymal transition in triple negative breast cancer cells by regulating β-catenin.Journal of cancer research and clinical oncology · 2025Article
- Deep learning-based classification of breast cancer molecular subtypes from H&E whole-slide images.Journal of pathology informatics · 2025Article
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer intrinsic molecular subtype (IMS) as classified by the expression-based PAM50 assay is considered a strong prognostic feature, even when controlled for by standard clinicopathological features such as age, grade, and nodal status, yet the molecular testing required to elucidate these subtypes is not routinely performed. Furthermore, when such bulk assays as RNA sequencing are performed, intratumoral heterogeneity that may affect prognosis and therapeutic decision-making can be missed.
methodsAs a more facile and readily available method for determining IMS in breast cancer, we developed a deep learning approach for approximating PAM50 intrinsic subtyping using only whole-slide images of H&E-stained breast biopsy tissue sections. This algorithm was trained on images from 443 tumors that had previously undergone PAM50 subtyping to classify small patches of the images into four major molecular subtypes-Basal-like, HER2-enriched, Luminal A, and Luminal B-as well as Basal vs. non-Basal. The algorithm was subsequently used for subtype classification of a held-out set of 222 tumors.
resultsThis deep learning image-based classifier correctly subtyped the majority of samples in the held-out set of tumors. However, in many cases, significant heterogeneity was observed in assigned subtypes across patches from within a single whole-slide image. We performed further analysis of heterogeneity, focusing on contrasting Luminal A and Basal-like subtypes because classifications from our deep learning algorithm-similar to PAM50-are associated with significant differences in survival between these two subtypes. Patients with tumors classified as heterogeneous were found to have survival intermediate between Luminal A and Basal patients, as well as more varied levels of hormone receptor expression patterns.
conclusionsHere, we present a method for minimizing manual work required to identify cancer-rich patches among all multiscale patches in H&E-stained WSIs that can be generalized to any indication. These results suggest that advanced deep machine learning methods that use only routinely collected whole-slide images can approximate RNA-seq-based molecular tests such as PAM50 and, importantly, may increase detection of heterogeneous tumors that may require more detailed subtype analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.